Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases
Authors:
Open Access
- 18 April 2026
- journal article
- research article
- Published by Springer Nature in Oncology and Therapy
- Vol. 14 (2) , 827-839
Abstract
Introduction Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved in the USA for relapsed or refractory multiple myeloma (RRMM) as early as following first relapse, based on pivotal CARTITUDE-1 (≥ 4 prior lines of therapy [LOT]) and CARTITUDE-4 (1–3 prior LOT) trials, which reported high response rates and prolonged survival. In CARTITUDE-1 and CARTITUDE-4, rates of all-grade parkinsonism were 6% and < 1%, respectively, while rates of cranial nerve palsy were 3% and 9%, respectively. This study aimed to characterize new-onset nonimmune effector cell-associated neurotoxicity syndrome (non-ICANS) neurologic events (NEs) among patients with RRMM receiving cilta-cel after 1–3 or ≥ 4 prior LOT. Methods This retrospective study used two real-world data sources: open and closed insurance claims from the Komodo Research Database (February 2021–November 2024), and electronic medical records from Loopback Analytics (February 2021–December 2024). New-onset non-ICANS NEs, including parkinsonism, cranial nerve palsy, and Guillain–Barré syndrome, were assessed from cilta-cel infusion until the end of clinical activity, death, or end of data availability. Analyses were conducted separately by database and stratified by LOT. Results In patients with 1–3 prior LOT (Komodo: 124; Loopback: 79), over a median follow-up of 3.4–3.5 months, cranial nerve palsy occurred in 5.6% and 5.1% in Komodo and Loopback, respectively, with no parkinsonism or Guillain–Barré syndrome observed. In patients with ≥ 4 prior LOT (Komodo: 524; Loopback: 191), over a median follow-up of 13.2–13.3 months, parkinsonism occurred in 1.0% in both databases, cranial nerve palsy in 4.6% and 1.0%, and Guillain–Barré syndrome in 0.2% and 0.5% in Komodo and Loopback, respectively. Conclusions In this real-world study, rates of non-ICANS NEs post-cilta-cel infusion across two databases were comparable to or lower than prior trials or real-world studies, reinforcing the favorable risk–benefit profile of cilta-cel in routine practice. Graphical Abstract available for this article. Graphical Abstract The alternative text for this image may have been generated using AI.Keywords
Funding Information
- Johnson and Johnson
- Legend Biotech
This publication has 17 references indexed in Scilit:
- Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaBlood Cancer Journal, 2025
- Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysisBlood, 2025
- Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapyJournal of Neurology, Neurosurgery & Psychiatry, 2025
- Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeThe Lancet Oncology, 2025
- Real-world data: bridging the gap between clinical trials and practiceeClinicalMedicine, 2024
- CAR T therapies in multiple myeloma: unleashing the futureCancer Gene Therapy, 2024
- GUILLAIN-BARRÉ SYNDROME FOLLOWING ANTI-BCMA CAR-T CELL THERAPYChest, 2023
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011